
Richard G White

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9293272/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cost-effectiveness of routine adolescent vaccination with an M72/AS01E-like tuberculosis vaccine in South Africa and India. Nature Communications, 2022, 13, 602.	5.8	13
2	Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test case. Vaccine, 2022, 40, 1681-1690.	1.7	9
3	Estimating the contribution of transmission in primary healthcare clinics to community-wide TB disease incidence, and the impact of infection prevention and control interventions, in KwaZulu-Natal, South Africa. BMJ Global Health, 2022, 7, e007136.	2.0	6
4	Updating age-specific contact structures to match evolving demography in a dynamic mathematical model of tuberculosis vaccination. PLoS Computational Biology, 2022, 18, e1010002.	1.5	1
5	Mathematical Modelling for Optimal Vaccine Dose Finding: Maximising Efficacy and Minimising Toxicity. Vaccines, 2022, 10, 756.	2.1	2
6	Potential implementation strategies, acceptability, and feasibility of new and repurposed TB vaccines. PLOS Global Public Health, 2022, 2, e0000076.	0.5	7
7	End-point definition and trial design to advance tuberculosis vaccine development. European Respiratory Review, 2022, 31, 220044.	3.0	7
8	Population benefits of addressing programmatic and social determinants of gender disparities in tuberculosis in Viet Nam: A modelling study. PLOS Global Public Health, 2022, 2, e0000784.	0.5	1
9	Ongoing challenges to understanding multidrug- and rifampicin-resistant tuberculosis in children <i>versus</i> adults. European Respiratory Journal, 2021, 57, 2002504.	3.1	4
10	Optimising Vaccine Dose in Inoculation against SARS-CoV-2, a Multi-Factor Optimisation Modelling Study to Maximise Vaccine Safety and Efficacy. Vaccines, 2021, 9, 78.	2.1	15
11	The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China. BMC Medicine, 2021, 19, 60.	2.3	20
12	Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. Lancet Infectious Diseases, The, 2021, 21, 354-365.	4.6	84
13	Affordability of Adult Tuberculosis Vaccination in India and China: A Dynamic Transmission Model-Based Analysis. Vaccines, 2021, 9, 245.	2.1	6
14	Regional differences in the care and outcomes of acute stroke patients in Australia: an observational study using evidence from the Australian Stroke Clinical Registry (AuSCR). BMJ Open, 2021, 11, e040418.	0.8	17
15	Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. The Lancet Global Health, 2021, 9, e841-e853.	2.9	34
16	Estimating ventilation rates in rooms with varying occupancy levels: Relevance for reducing transmission risk of airborne pathogens. PLoS ONE, 2021, 16, e0253096.	1.1	10
17	The impact of COVID-19 on TB: a review of the data. International Journal of Tuberculosis and Lung Disease, 2021, 25, 436-446.	0.6	165
18	Gestational age recorded at delivery versus estimations using antenatal care data from the Electronic Maternal and Child Health Registry in the West Bank: a comparative analysis. Lancet, The, 2021, 398, S31.	6.3	0

#	Article	IF	CITATIONS
19	An approach for improving the quality of country-level TB modelling. International Journal of Tuberculosis and Lung Disease, 2021, 25, 614-619.	0.6	3
20	Validity of the Gender Dysphoria diagnosis and incidence trends in Sweden: a nationwide register study. Scientific Reports, 2021, 11, 16168.	1.6	11
21	Better data for country-level TB resource allocation are urgently required. International Journal of Tuberculosis and Lung Disease, 2021, 25, 662-664.	0.6	0
22	Disregarding the restrictive vial-opening policy for BCG vaccine in Guinea-Bissau: impact and cost-effectiveness for tuberculosis mortality and all-cause mortality in children aged 0–4 years. BMJ Global Health, 2021, 6, e006127.	2.0	6
23	Impact of the Covid-19 epidemic and related social distancing regulations on social contact and SARS-CoV-2 transmission potential in rural South Africa: analysis of repeated cross-sectional surveys. BMC Infectious Diseases, 2021, 21, 928.	1.3	13
24	Heavy weather events, water quality and gastroenteritis in Norway. One Health, 2021, 13, 100297.	1.5	4
25	Self-clearance of <i>Mycobacterium tuberculosis</i> infection: implications for lifetime risk and population at-risk of tuberculosis disease. Proceedings of the Royal Society B: Biological Sciences, 2021, 288, 20201635.	1.2	25
26	Modelling the effect of infection prevention and control measures on rate of <i>Mycobacterium tuberculosis</i> transmission to clinic attendees in primary health clinics in South Africa. BMJ Global Health, 2021, 6, e007124.	2.0	11
27	Impact of COVID-19 Disruptions on Global BCG Coverage and Paediatric TB Mortality: A Modelling Study. Vaccines, 2021, 9, 1228.	2.1	15
28	The impact of blood transcriptomic biomarker targeted tuberculosis preventive therapy in people living with HIV: a mathematical modelling study. BMC Medicine, 2021, 19, 252.	2.3	4
29	Sociological variety and the transmission efficiency of <i>Mycobacterium tuberculosis </i> : a secondary analysis of qualitative and quantitative data from 15 communities in Zambia. BMJ Open, 2021, 11, e047136.	0.8	3
30	The effect of new <i>Mycobacterium tuberculosis</i> infection on the sensitivity of prognostic TB signatures. International Journal of Tuberculosis and Lung Disease, 2021, 25, 1001-1005.	0.6	1
31	Potential impact of tuberculosis vaccines in China, South Africa, and India. Science Translational Medicine, 2020, 12, .	5.8	42
32	The predicted impact of tuberculosis preventive therapy: the importance of disease progression assumptions. BMC Infectious Diseases, 2020, 20, 880.	1.3	6
33	No antimicrobial resistance research agenda without tuberculosis. The Lancet Global Health, 2020, 8, e987-e988.	2.9	4
34	New tuberculosis vaccines: advances in clinical development and modelling. Journal of Internal Medicine, 2020, 288, 661-681.	2.7	29
35	Informing Balanced Investment in Services and Health Systems: A Case Study of Priority Setting for Tuberculosis Interventions in South Africa. Value in Health, 2020, 23, 1462-1469.	0.1	5
36	The risk of multidrug- or rifampicin-resistance in males <i>versus</i> females with tuberculosis. European Respiratory Journal, 2020, 56, 2000626.	3.1	16

#	Article	IF	CITATIONS
37	The potential impact of COVID-19-related disruption on tuberculosis burden. European Respiratory Journal, 2020, 56, 2001718.	3.1	166
38	Immunologic Dose-Response to Adenovirus-Vectored Vaccines in Animals and Humans: A Systematic Review of Dose-Response Studies of Replication Incompetent Adenoviral Vaccine Vectors when Given via an Intramuscular or Subcutaneous Route. Vaccines, 2020, 8, 131.	2.1	15
39	Does sunlight drive seasonality of TB in Vietnam? A retrospective environmental ecological study of tuberculosis seasonality in Vietnam from 2010 to 2015. BMC Infectious Diseases, 2020, 20, 184.	1.3	17
40	Response Type and Host Species may be Sufficient to Predict Dose-Response Curve Shape for Adenoviral Vector Vaccines. Vaccines, 2020, 8, 155.	2.1	4
41	Systematic Review and Meta-Analysis of Sex Differences in Social Contact Patterns and Implications for Tuberculosis Transmission and Control. Emerging Infectious Diseases, 2020, 26, 910-919.	2.0	25
42	Tuberculosis from transmission in clinics in high HIV settings may be far higher than contact data suggest. International Journal of Tuberculosis and Lung Disease, 2020, 24, 403-408.	0.6	13
43	Should NICE reconsider the 2016 UK guidelines on TB contact tracing? A cost-effectiveness analysis of contact investigations in London. Thorax, 2019, 74, 185-193.	2.7	5
44	Guidelines for multi-model comparisons of the impact of infectious disease interventions. BMC Medicine, 2019, 17, 163.	2.3	39
45	Investigating the effect of lifestyle risk factors upon number of aspirated and mature oocytes in in vitro fertilization cycles: Interaction with antral follicle count. PLoS ONE, 2019, 14, e0221015.	1.1	11
46	Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy. Scientific Reports, 2019, 9, 11126.	1.6	13
47	Potential effect of age of BCG vaccination on global paediatric tuberculosis mortality: a modelling study. The Lancet Global Health, 2019, 7, e1655-e1663.	2.9	31
48	Improving the quality of modelling evidence used for tuberculosis policy evaluation. International Journal of Tuberculosis and Lung Disease, 2019, 23, 387-395.	0.6	4
49	Spotting the old foe—revisiting the case definition for TB. Lancet Respiratory Medicine,the, 2019, 7, 199-201.	5.2	19
50	Estimating the Impact of Tuberculosis Case Detection in Constrained Health Systems: An Example of Case-Finding in South Africa. American Journal of Epidemiology, 2019, 188, 1155-1164.	1.6	13
51	Estimating age-mixing patterns relevant for the transmission of airborne infections. Epidemics, 2019, 28, 100339.	1.5	8
52	Application of provincial data in mathematical modelling to inform sub-national tuberculosis program decision-making in South Africa. PLoS ONE, 2019, 14, e0209320.	1.1	9
53	The way forward for tuberculosis vaccines. Lancet Respiratory Medicine,the, 2019, 7, 204-206.	5.2	7
54	Evaluating costs and health consequences of sick leave strategies against pandemic and seasonal influenza in Norway using a dynamic model. BMJ Open, 2019, 9, e027832.	0.8	6

#	Article	IF	CITATIONS
55	Dose finding for new vaccines: The role for immunostimulation/immunodynamic modelling. Journal of Theoretical Biology, 2019, 465, 51-55.	0.8	30
56	Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study. The Lancet Global Health, 2019, 7, e209-e218.	2.9	45
57	Mycobacterium tuberculosis transmission in an ethnically-diverse high incidence region in England, 2007–11. BMC Infectious Diseases, 2019, 19, 26.	1.3	5
58	Clinical Development of New TB Vaccines: Recent Advances and Next Steps. Frontiers in Microbiology, 2019, 10, 3154.	1.5	56
59	Stratification by interferon-Î ³ release assay level predicts risk of incident TB. Thorax, 2018, 73, 652-661.	2.7	49
60	Approximate Bayesian Computation and Simulation-Based Inference for Complex Stochastic Epidemic Models. Statistical Science, 2018, 33, .	1.6	46
61	Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway. Pharmacoeconomics, 2018, 36, 591-601.	1.7	13
62	Small contribution of gold mines to the ongoing tuberculosis epidemic in South Africa: a modeling-based study. BMC Medicine, 2018, 16, 52.	2.3	11
63	An explanation for the low proportion of tuberculosis that results from transmission between household and known social contacts. Scientific Reports, 2018, 8, 5382.	1.6	47
64	Transmission events revealed in tuberculosis contact investigations in London. Scientific Reports, 2018, 8, 6676.	1.6	4
65	Investigating the impact of TB case-detection strategies and the consequences of false positive diagnosis through mathematical modelling. BMC Infectious Diseases, 2018, 18, 340.	1.3	7
66	Systematic neglect of men as a key population in tuberculosis. Tuberculosis, 2018, 113, 249-253.	0.8	14
67	Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making. Npj Vaccines, 2018, 3, 36.	2.9	16
68	Choice of time horizon critical in estimating costs and effects of changes to HIV programmes. PLoS ONE, 2018, 13, e0196480.	1.1	2
69	A Longitudinal Study of Road Traffic Noise and Body Mass Index Trajectories from Birth to 8 Years. Epidemiology, 2018, 29, 729-738.	1.2	18
70	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	6.3	638
71	A Bayesian Approach to Understanding Sex Differences in Tuberculosis Disease Burden. American Journal of Epidemiology, 2018, 187, 2431-2438.	1.6	26
72	Evidence-informed policy making at country level: lessons learned from the South African Tuberculosis Think Tank. International Journal of Tuberculosis and Lung Disease, 2018, 22, 606-613.	0.6	19

#	Article	IF	CITATIONS
73	Global tuberculosis targets and milestones set for 2016–2035: definition and rationale. International Journal of Tuberculosis and Lung Disease, 2018, 22, 723-730.	0.6	81
74	Empirical estimation of resource constraints for use in model-based economic evaluation: an example of TB services in South Africa. Cost Effectiveness and Resource Allocation, 2018, 16, 27.	0.6	20
75	Using Data from Macaques To Predict Gamma Interferon Responses after Mycobacterium bovis BCG Vaccination in Humans: a Proof-of-Concept Study of Immunostimulation/Immunodynamic Modeling Methods. Vaccine Journal, 2017, 24, .	3.2	7
76	Lower inflammatory markers in women with antenatal depression brings the M1/M2 balance into focus from a new direction. Psychoneuroendocrinology, 2017, 80, 15-25.	1.3	48
77	Inflammatory markers in late pregnancy in association with postpartum depression—A nested case-control study. Psychoneuroendocrinology, 2017, 79, 146-159.	1.3	51
78	An evaluation of tuberculosis contact investigations against national standards. Thorax, 2017, 72, 736-745.	2.7	27
79	A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	17
80	Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study. The Lancet Global Health, 2017, 5, e1123-e1132.	2.9	41
81	Efficient History Matching of a High Dimensional Individual-Based HIV Transmission Model. SIAM-ASA Journal on Uncertainty Quantification, 2017, 5, 694-719.	1.1	21
82	History Matching of A Complex Epidemiological Model of Human Immunodeficiency Virus Transmission By Using Variance Emulation. Journal of the Royal Statistical Society Series C: Applied Statistics, 2017, 66, 717-740.	0.5	26
83	Impact of Targeted Tuberculosis Vaccination Among a Mining Population in South Africa: A Model-Based Study. American Journal of Epidemiology, 2017, 186, 1362-1369.	1.6	13
84	Wildlife-livestock interactions and risk areas for cross-species spread of bovine tuberculosis. Onderstepoort Journal of Veterinary Research, 2017, 84, e1-e10.	0.6	26
85	Modelling the social and structural determinants of tuberculosis: opportunities and challenges. International Journal of Tuberculosis and Lung Disease, 2017, 21, 957-964.	0.6	38
86	The impact of methicillin-resistant S. aureus on length of stay, readmissions and costs: a register based case-control study of patients hospitalized in Norway. Antimicrobial Resistance and Infection Control, 2017, 6, 74.	1.5	27
87	Universal test, treat, and keep: improving ART retention is key in cost-effective HIV control in Uganda. BMC Infectious Diseases, 2017, 17, 322.	1.3	31
88	Improving ART programme retention and viral suppression are key to maximising impact of treatment as prevention – a modelling study. BMC Infectious Diseases, 2017, 17, 557.	1.3	7
89	Age- and Sex-Specific Social Contact Patterns and Incidence of <i>Mycobacterium tuberculosis</i> Infection. American Journal of Epidemiology, 2016, 183, kwv160.	1.6	110
90	A novel blood test for tuberculosis prevention and treatment. South African Medical Journal, 2016, 107, 4.	0.2	7

#	Article	IF	CITATIONS
91	Sex Differences in Tuberculosis Burden and Notifications in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. PLoS Medicine, 2016, 13, e1002119.	3.9	277
92	Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy. Aids, 2016, 30, 1279-1286.	1.0	17
93	Time for men to count, too. International Journal of Tuberculosis and Lung Disease, 2016, 20, 425-425.	0.6	1
94	The TB vaccine H56+IC31 dose-response curve is peaked not saturating: Data generation for new mathematical modelling methods to inform vaccine dose decisions. Vaccine, 2016, 34, 6285-6291.	1.7	22
95	A Systematic Review of Published Respondent-Driven Sampling Surveys Collecting Behavioral and Biologic Data. AIDS and Behavior, 2016, 20, 1754-1776.	1.4	59
96	The potential impact of BCG vaccine supply shortages on global paediatric tuberculosis mortality. BMC Medicine, 2016, 14, 138.	2.3	39
97	Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines. Human Vaccines and Immunotherapeutics, 2016, 12, 2813-2832.	1.4	78
98	Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. The Lancet Global Health, 2016, 4, e806-e815.	2.9	138
99	Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. The Lancet Clobal Health, 2016, 4, e816-e826.	2.9	69
100	Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis. BMC Infectious Diseases, 2016, 16, 726.	1.3	28
101	Comparison of indoor contact time data in Zambia and Western Cape, South Africa suggests targeting of interventions to reduce Mycobacterium tuberculosis transmission should be informed by local data. BMC Infectious Diseases, 2016, 16, 71.	1.3	12
102	Coverage of clinic-based TB screening in South Africa may be low in key risk groups. Public Health Action, 2016, 6, 19-21.	0.4	7
103	Ebola: the hidden toll of tuberculosis. Public Health Action, 2016, 6, 2-2.	0.4	1
104	TIME Impact $\hat{a} \in $ a new user-friendly tuberculosis (TB) model to inform TB policy decisions. BMC Medicine, 2016, 14, 56.	2.3	42
105	The transmission of Mycobacterium tuberculosis in high burden settings. Lancet Infectious Diseases, The, 2016, 16, 227-238.	4.6	149
106	Effect of pre-exposure prophylaxis and combination HIV prevention for men who have sex with men in the UK: a mathematical modelling study. Lancet HIV,the, 2016, 3, e94-e104.	2.1	68
107	Individual-level factors associated with variation in mycobacterial-specific immune response: Gender and previous BCG vaccination status. Tuberculosis, 2016, 96, 37-43.	0.8	6
108	A novel blood test for tuberculosis prevention and treatment. South African Medical Journal, 2016, 107, 4.	0.2	7

#	Article	IF	CITATIONS
109	Risk factors associated with Rift Valley fever epidemics in South Africa in 2008–11. Scientific Reports, 2015, 5, 9492.	1.6	25
110	To improve our tuberculosis burden estimates we need to learn from each other. International Journal of Tuberculosis and Lung Disease, 2015, 19, 255-255.	0.6	0
111	Regarding the effect of cured tuberculosis disease on longevity. International Journal of Tuberculosis and Lung Disease, 2015, 19, 367-367.	0.6	0
112	Tuberculosis Prevention in South Africa. PLoS ONE, 2015, 10, e0122514.	1.1	17
113	Risk Factors for Sporadic Domestically Acquired Campylobacter Infections in Norway 2010–2011: A National Prospective Case-Control Study. PLoS ONE, 2015, 10, e0139636.	1.1	41
114	The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa. PLoS ONE, 2015, 10, e0145796.	1.1	10
115	Bayesian History Matching of Complex Infectious Disease Models Using Emulation: A Tutorial and a Case Study on HIV in Uganda. PLoS Computational Biology, 2015, 11, e1003968.	1.5	97
116	Modelling the HIV epidemic among MSM in the United Kingdom. Aids, 2015, 29, 339-349.	1.0	39
117	Tuberculosis Control in South African Gold Mines: Mathematical Modeling of a Trial of Community-Wide Isoniazid Preventive Therapy. American Journal of Epidemiology, 2015, 181, 619-632.	1.6	38
118	The Distribution of Fitness Costs of Resistance-Conferring Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis. Clinical Infectious Diseases, 2015, 61, S147-S154.	2.9	40
119	Accelerating progress towards tuberculosis elimination: the need for combination treatment and prevention. International Journal of Tuberculosis and Lung Disease, 2015, 19, 5-9.	0.6	20
120	Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: "STROBE-RDS―statement. Journal of Clinical Epidemiology, 2015, 68, 1463-1471.	2.4	177
121	Population-Level Impact of Shorter-Course Regimens for Tuberculosis: A Model-Based Analysis. PLoS ONE, 2014, 9, e96389.	1.1	10
122	Ability of preventive therapy to cure latent <i>Mycobacterium tuberculosis</i> infection in HIV-infected individuals in high-burden settings. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5325-5330.	3.3	49
123	The dual impact of antiretroviral therapy and sexual behaviour changes on HIV epidemiologic trends in Uganda: a modelling study. Sexually Transmitted Infections, 2014, 90, 423-429.	0.8	13
124	Using the TIME model in Spectrum to estimate tuberculosis–HIV incidence and mortality. Aids, 2014, 28, S477-S487.	1.0	7
125	Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15520-15525.	3.3	153
126	The effect of diabetes and undernutrition trends on reaching 2035 global tuberculosis targets. Lancet Diabetes and Endocrinology,the, 2014, 2, 754-764.	5.5	102

#	Article	IF	CITATIONS
127	Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis. Open Forum Infectious Diseases, 2014, 1, ofu073.	0.4	15
128	Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health, 2014, 2, e23-e34.	2.9	188
129	Looking upstream to prevent HIV transmission. Aids, 2014, 28, 891-899.	1.0	39
130	The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa. Aids, 2014, 28, S25-S34.	1.0	33
131	How can mathematical models advance tuberculosis control in high HIV prevalence settings?. International Journal of Tuberculosis and Lung Disease, 2014, 18, 509-514.	0.6	25
132	Towards elimination in industrialised countries: expanding diagnosis and treatment of LTBI among immigrants [Editorial]. International Journal of Tuberculosis and Lung Disease, 2014, 18, 380-380.	0.6	4
133	Estimation of the HIV Basic Reproduction Number in Rural South West Uganda: 1991–2008. PLoS ONE, 2014, 9, e83778.	1.1	18
134	Modeling of Novel Diagnostic Strategies for Active Tuberculosis – A Systematic Review: Current Practices and Recommendations. PLoS ONE, 2014, 9, e110558.	1.1	23
135	The Impact of Antiretroviral Therapy on Mortality in HIV Positive People during Tuberculosis Treatment: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e112017.	1.1	63
136	Transmission Potential of Rift Valley Fever Virus over the Course of the 2010 Epidemic in South Africa. Emerging Infectious Diseases, 2013, 19, 916-924.	2.0	21
137	Does the â€~inverse equity hypothesis' explain how both poverty and wealth can be associated with HIV prevalence in sub-Saharan Africa?. Journal of Epidemiology and Community Health, 2013, 67, 526-529.	2.0	21
138	Heterosexual HIV-1 Infectiousness and Antiretroviral Use. Epidemiology, 2013, 24, 110-121.	1.2	79
139	Effect of HSV â€2 on populationâ€level trends in HIV incidence in U ganda between 1990 and 2007. Tropical Medicine and International Health, 2013, 18, 1257-1266.	1.0	8
140	Community understanding of respondent-driven sampling in a medical research setting in Uganda: importance for the use of RDS for public health research. International Journal of Social Research Methodology: Theory and Practice, 2013, 16, 269-284.	2.3	9
141	Predicting the Long-Term Impact of Antiretroviral Therapy Scale-Up on Population Incidence of Tuberculosis. PLoS ONE, 2013, 8, e75466.	1.1	24
142	Respondent Driven Sampling: Determinants of Recruitment and a Method to Improve Point Estimation. PLoS ONE, 2013, 8, e78402.	1.1	27
143	Exploratory Space-Time Analyses of Rift Valley Fever in South Africa in 2008–2011. PLoS Neglected Tropical Diseases, 2012, 6, e1808.	1.3	41
144	Respondent driven sampling—where we are and where should we be going?: TableÂ1. Sexually Transmitted Infections, 2012, 88, 397-399.	0.8	62

#	Article	IF	CITATIONS
145	HIV Treatment as Prevention: Optimising the Impact of Expanded HIV Treatment Programmes. PLoS Medicine, 2012, 9, e1001258.	3.9	50
146	HIV Treatment as Prevention: Models, Data, and Questions—Towards Evidence-Based Decision-Making. PLoS Medicine, 2012, 9, e1001259.	3.9	64
147	Evaluation of Respondent-driven Sampling. Epidemiology, 2012, 23, 138-147.	1.2	229
148	Exploring the Potential Impact of a Reduction in Partnership Concurrency on HIV Incidence in Rural Uganda. Sexually Transmitted Diseases, 2012, 39, 407-413.	0.8	25
149	HIV and STI Prevalence and Determinants among Male Migrant Workers in India. PLoS ONE, 2012, 7, e43576.	1.1	13
150	Calibrating Models in Economic Evaluation. Pharmacoeconomics, 2011, 29, 35-49.	1.7	123
151	Role of acute infection in HIV transmission. Lancet, The, 2011, 378, 1913-1914.	6.3	4
152	Antiretroviral Treatment Cohort Analysis Using Time-Updated CD4 Counts: Assessment of Bias with Different Analytic Methods. PLoS ONE, 2011, 6, e27763.	1.1	3
153	Periodic Active Case Finding for TB: When to Look?. PLoS ONE, 2011, 6, e29130.	1.1	22
154	P1-S4.20 Mathematical modelling of HIV transmission and control among men who have sex with men: a review of 25 years of literature. Sexually Transmitted Infections, 2011, 87, A169-A169.	0.8	0
155	Antiretroviral therapy and sexual behavior in Uganda: a cohort study. Aids, 2011, 25, 671-678.	1.0	24
156	S13.3 An empirical evaluation of respondent-driven sampling. Sexually Transmitted Infections, 2011, 87, A15-A16.	0.8	1
157	Mathematical models for the study of HIV spread and control amongst men who have sex with men. European Journal of Epidemiology, 2011, 26, 695-709.	2.5	21
158	Evaluation of the role of location and distance in recruitment in respondent-driven sampling. International Journal of Health Geographics, 2011, 10, 56.	1.2	29
159	The role of the natural epidemic dynamics and migration in explaining the course of the HIV epidemic in rural Uganda: a modelling study. International Journal of Epidemiology, 2011, 40, 397-404.	0.9	1
160	Attempting to explain heterogeneous HIV epidemics in sub-Saharan Africa: potential role of historical changes in risk behaviour and male circumcision. Sexually Transmitted Infections, 2011, 87, 640-645.	0.8	7
161	Rift Valley Fever Epidemiology, Surveillance, and Control: What Have Models Contributed?. Vector-Borne and Zoonotic Diseases, 2011, 11, 761-771.	0.6	45
162	Attaining realistic and substantial reductions in HIV incidence: model projections of combining microbicide and male circumcision interventions in rural Uganda. Sexually Transmitted Infections, 2011, 87, 635-639.	0.8	8

#	Article	IF	CITATIONS
163	Population Density, Water Supply, and the Risk of Dengue Fever in Vietnam: Cohort Study and Spatial Analysis. PLoS Medicine, 2011, 8, e1001082.	3.9	175
164	Concurrency is more complex than it seems. Aids, 2010, 24, 313-315.	1.0	38
165	Infectiousness of HIV-infected homosexual men in the era of highly active antiretroviral therapy. Aids, 2010, 24, 2418-2420.	1.0	13
166	Calibration of Disease Simulation Model Using an Engineering Approach. Value in Health, 2010, 13, 157.	0.1	4
167	Do behavioural differences help to explain variations in HIV prevalence in adolescents in sub-Saharan Africa?. Tropical Medicine and International Health, 2010, 15, 554-566.	1.0	34
168	Polygyny and symmetric concurrency: comparing long-duration sexually transmitted infection prevalence using simulated sexual networks. Sexually Transmitted Infections, 2010, 86, 553-558.	0.8	11
169	HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. International Journal of Epidemiology, 2010, 39, 1048-1063.	0.9	574
170	Strong Association Between In-Migration and HIV Prevalence in Urban Sub-Saharan Africa. Sexually Transmitted Diseases, 2010, 37, 240-243.	0.8	59
171	Male Circumcision for HIV Prevention in High HIV Prevalence Settings: What Can Mathematical Modelling Contribute to Informed Decision Making?. PLoS Medicine, 2009, 6, e1000109.	3.9	118
172	A network-level explanation for the differences in HIV prevalence in South Africa's racial groups. African Journal of AIDS Research, 2009, 8, 243-254.	0.3	38
173	Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa. Vaccine, 2009, 27, 940-946.	1.7	44
174	Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infectious Diseases, The, 2009, 9, 118-129.	4.6	725
175	Curable Sexually Transmitted Infection Treatment Interventions to Prevent HIV Transmission in Sub-Saharan Africa. The Open Infectious Diseases Journal, 2009, 3, 148-155.	0.6	6
176	Control of sexually transmitted infections for HIV prevention. Lancet, The, 2008, 372, 1297.	6.3	8
177	Low effectiveness of syndromic treatment services for curable sexually transmitted infections in rural South Africa. Sexually Transmitted Infections, 2008, 84, 528-534.	0.8	42
178	Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa. Sexually Transmitted Infections, 2008, 84, ii12-ii18.	0.8	20
179	Systematic review of orogenital HIV-1 transmission probabilities. International Journal of Epidemiology, 2008, 37, 1255-1265.	0.9	61
180	Behaviour change and competitive exclusion can explain the diverging HIV-1 and HIV-2 prevalence trends in Guinea–Bissau. Epidemiology and Infection, 2008, 136, 551-561.	1.0	24

#	Article	IF	CITATIONS
181	Treating Curable Sexually Transmitted Infections to Prevent HIV in Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 346-353.	0.9	56
182	Male circumcision for HIV prevention in sub-Saharan Africa: who, what and when?. Aids, 2008, 22, 1841-1850.	1.0	83
183	Understanding the Impact of Male Circumcision Interventions on the Spread of HIV in Southern Africa. PLoS ONE, 2008, 3, e2212.	1.1	122
184	Understanding the differences between contrasting HIV epidemics in east and west Africa: results from a simulation model of the Four Cities Study. Sexually Transmitted Infections, 2007, 83, i5-i16.	0.8	66
185	Quantifying HIV-1 transmission due to contaminated injections. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 9794-9799.	3.3	24
186	PERIOD AND COHORT DYNAMICS IN FERTILITY NORMS AT THE ONSET OF THE DEMOGRAPHIC TRANSITION IN KENYA 1978–1998. Journal of Biosocial Science, 2007, 39, 443-454.	0.5	4
187	Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics. Sexually Transmitted Infections, 2007, 83, i17-i24.	0.8	96
188	Confusing association with causation?, a response to Brewer et al., â€~Valid evaluation of iatrogenic and sexual HIV transmission requires proof'. Aids, 2007, 21, 2558-2559.	1.0	2
189	Response to Gray's Letter. Sexually Transmitted Diseases, 2007, 34, 62.	0.8	0
190	HIV epidemic trend and antiretroviral treatment need in Karonga District, Malawi. Epidemiology and Infection, 2007, 135, 922-932.	1.0	30
191	Healthcare Costs of Acute and Chronic Pain Associated with a Diagnosis of Herpes Zoster. Journal of the American Geriatrics Society, 2007, 55, 1168-1175.	1.3	67
192	HIV incidence and recent injections among adults in rural southwestern Uganda. Aids, 2007, 21, 1056-1058.	1.0	14
193	Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. Aids, 2006, 20, 805-812.	1.0	169
194	Empirical Observations Underestimate the Proportion of Human Immunodeficiency Virus Infections Attributable to Sexually Transmitted Diseases in the Mwanza and Rakai Sexually Transmitted Disease Treatment Trials: Simulation Results. Sexually Transmitted Diseases, 2006, 33, 536-544.	0.8	53
195	How Important Are Unsafe Medical Injections in the Spread of HIV in Africa?. Sexually Transmitted Diseases, 2006, 33, 135-136.	0.8	2
196	Amplified HIV Transmission during Earlyâ€&tage Infection. Journal of Infectious Diseases, 2006, 193, 604-605.	1.9	36
197	Determinants of the Impact of Sexually Transmitted Infection Treatment on Prevention of HIV Infection: A Synthesis of Evidence from the Mwanza, Rakai, and Masaka Intervention Trials. Journal of Infectious Diseases, 2005, 191, S168-S178.	1.9	125
198	Transmission of HIV via unsafe injection or unsafe sex? Anomalies or misunderstanding?. International Journal of STD and AIDS, 2004, 15, 61-63.	0.5	5

#	Article	IF	CITATIONS
199	Can Population Differences Explain the Contrasting Results of the Mwanza, Rakai, and Masaka HIV/Sexually Transmitted Disease Intervention Trials?. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1500-1513.	0.9	84
200	Commentary: What can we make of an association between human immunodeficiency virus prevalence and population mobility?. International Journal of Epidemiology, 2003, 32, 753-754.	0.9	20
201	Comparison of STD prevalences in the Mwanza, Rakai, and Masaka trial populations: the role of selection bias and diagnostic errors. Sexually Transmitted Infections, 2003, 79, 98-105.	0.8	41
202	Higher risk behaviour and rates of sexually transmitted diseases in Mwanza compared to Uganda may help explain HIV prevention trial outcomes. Aids, 2003, 17, 2653-2660.	1.0	33
203	DETERMINANTS OF COITAL FREQUENCY AMONG MARRIED WOMEN IN CENTRAL AFRICAN REPUBLIC: THE ROLE OF FEMALE GENITAL CUTTING. Journal of Biosocial Science, 2002, 34, 525-539.	0.5	32
204	Monitoring the AIDS epidemic using HIV prevalence data among young women attending antenatal clinics: prospects and problems. Aids, 2000, 14, 1633-1645.	1.0	94
205	Links between premarital sexual behaviour and extramarital intercourse: a multi-site analysis. Aids, 2000, 14, 2323-2331.	1.0	62
206	Incubation of Steelhead Trout and Spring Chinook Salmon Eggs in a Moist Environment. Progressive Fish-Culturist, 1981, 43, 131-134.	0.6	8